Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-09-06 08:31 am Purchase | 2024-09-06 | 13D | Gyre Therapeutics, Inc. GYRE | Ma Songjiang | 7,456,847 7.620% | 7,456,847 (New Position) | Filing History |
| 2024-09-06 08:15 am Purchase | 2024-09-06 | 13D | Gyre Therapeutics, Inc. GYRE | Luo Ying | 8,458,983 8.540% | 8,458,983 (New Position) | Filing History |
| 2024-02-14 1:18 pm Unchanged | 2023-12-31 | 13G | Gyre Therapeutics, Inc. GYRE | Lytton, Laurence W. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-01-24 5:11 pm Unchanged | 2024-01-22 | 13D | Gyre Therapeutics, Inc. GYRE | GNI Group Ltd. | 73,313,885 85.340% | 0 (Unchanged) | Filing History |
| 2023-11-27 4:49 pm Unchanged | 2023-11-22 | 13D | Gyre Therapeutics, Inc. GYRE | GNI Group Ltd. | 73,313,885 85.360% | 0 (Unchanged) | Filing History |
| 2023-11-01 4:58 pm Purchase | 2023-10-30 | 13D | Gyre Therapeutics, Inc. GYRE | GNI Group Ltd. | 73,313,885 85.360% | 73,313,885 (New Position) | Filing History |
| 2023-10-30 7:28 pm Unchanged | 2023-10-27 | 13D | Catalyst Biosciences, Inc. CBIO | GNI Group Ltd. | 417,768 16.500% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:46 pm Sale | 2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO | Nantahala Capital Management, LLC | 29,204 1.400% | -670,969 (-95.83%) | Filing History |
| 2023-02-14 4:09 pm Sale | 2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO | ORBIMED ADVISORS LLC | 0 0.000% | -342,423 (Position Closed) | Filing History |
| 2023-02-13 2:55 pm Sale | 2022-12-31 | 13G | Catalyst Biosciences, Inc. CBIO | Lytton, Laurence W. | 177,822 7.100% | -294,793 (-62.37%) | Filing History |
| 2023-02-13 12:06 pm Sale | 2022-12-30 | 13G | Catalyst Biosciences, Inc. CBIO | Renaissance Technologies LLC | 79,132 3.140% | -370,105 (-82.39%) | Filing History |
| 2023-01-04 6:13 pm Purchase | 2022-12-26 | 13D | Catalyst Biosciences, Inc. CBIO | GNI Group Ltd. | 417,768 16.600% | 417,768 (New Position) | Filing History |
| 2022-10-07 07:45 am Sale | 2022-10-04 | 13D | Catalyst Biosciences, Inc. CBIO | SINGER JULIAN D. | 72,160 3.440% | -497,641 (-87.34%) | Filing History |
| 2022-09-22 4:15 pm Sale | 2022-09-21 | 13D | Catalyst Biosciences, Inc. CBIO | JEC II Associates LLC | 0 0.000% | -635,101 (Position Closed) | Filing History |
| 2022-08-19 4:30 pm Unchanged | 2022-08-18 | 13D | Catalyst Biosciences, Inc. CBIO | SINGER JULIAN D. | 569,801 7.100% | 0 (Unchanged) | Filing History |
| 2022-08-03 4:17 pm Unchanged | 2022-08-03 | 13D | Catalyst Biosciences, Inc. CBIO | SINGER JULIAN D. | 569,801 7.100% | 0 (Unchanged) | Filing History |
| 2022-08-01 4:15 pm Unchanged | 2022-07-31 | 13D | Catalyst Biosciences, Inc. CBIO | JEC II Associates LLC | 635,101 8.000% | 0 (Unchanged) | Filing History |
| 2022-07-22 2:21 pm Purchase | 2022-07-20 | 13D | Catalyst Biosciences, Inc. CBIO | SINGER JULIAN D. | 569,801 7.100% | 58,974 (+11.54%) | Filing History |
| 2022-07-01 4:15 pm Unchanged | 2022-06-29 | 13D | Catalyst Biosciences, Inc. CBIO | JEC II Associates LLC | 635,101 8.000% | 0 (Unchanged) | Filing History |
| 2022-06-21 5:02 pm Purchase | 2022-06-13 | 13D | Catalyst Biosciences, Inc. CBIO | JEC II Associates LLC | 635,101 8.000% | 635,101 (New Position) | Filing History |